Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director
|
|
Foamix Pharmaceuticals Ltd. (FOMX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/18/2020 |
GN
| Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea |
| 01/17/2020 |
GN
| Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics |
| 01/14/2020 |
GN
| Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S. |
| 12/31/2019 |
GN
| Rigrodsky & Long, P.A. Files Class Action Suit Against Foamix Pharmaceuticals Ltd. |
| 11/13/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders |
| 11/11/2019 |
GN
| Shareholder Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – FOMX, CISN, PEGI, AXE |
| 11/11/2019 |
GN
| Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update |
| 11/11/2019 |
GN
| Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications |
| 11/01/2019 |
GN
| Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11 |
| 10/23/2019 |
GN
| Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103 |
| 10/10/2019 |
GN
| Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference |
| 09/20/2019 |
GN
| Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference |
| 07/30/2019 |
GN
| Foamix Announces $64 Million Capital Financing Investment by Perceptive Advisors and OrbiMed |
| 07/24/2019 |
GN
| Foamix Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8 |
| 05/07/2019 |
GN
| Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update |
| 04/24/2019 |
GN
| Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8 |
| 03/08/2019 |
GN
| Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019 |
| 03/07/2019 |
GN
| Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne |
| 02/28/2019 |
GN
| Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update |
| 02/27/2019 |
GN
| Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year |
| 02/26/2019 |
GN
| Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting |
| 01/23/2019 |
GN
| Foamix Announces Appointment of Sharon Barbari to Board of Directors |
| 12/21/2018 |
GN
| Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne |
| 11/27/2018 |
GN
| Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer |
| 11/13/2018 |
GN
| Recent Analysis Shows WPX Energy, Verizon Communications, Innovative Industrial Properties, Foamix Pharmaceuticals, O2Micro International, and Investment Technology Group Market Influences — Renewed Outlook, Key Drivers of Growth |
| 11/07/2018 |
GN
| Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea |
| 10/29/2018 |
GN
| Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8 |
| 10/12/2018 |
GN
| Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference |
| 10/01/2018 |
GN
| Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne |
| 09/18/2018 |
GN
| Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters |
| 09/13/2018 |
GN
| Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares |
| 09/12/2018 |
GN
| Foamix Announces Proposed Follow-on Offering of Ordinary Shares |
| 09/11/2018 |
GN
| Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne |
| 08/01/2018 |
GN
| Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8 |
|
|
|